Dengue Vaccines Market Driving Growth Factors help to improve Business Scope in Near Future

Dengue fever, often known as breakbone fever, is a viral virus transmitted by mosquitos that causes a severe flu-like disease. Severe dengue fever is a potentially fatal consequence of the disease. Dengue vaccine is a human vaccination that prevents dengue disease. Dengue vaccination is only indicated for people who have experienced dengue fever before. It is administered in three injections over the course of a year.

Dengue Vaccines

The development of a dengue vaccine has reached a critical point, with a slew of pharmaceutical behemoths scheduled to report the results of large clinical trials launched over the last decade or half-decade. The present Denvaxia® vaccine's exclusivity is expected to be broken by the availability of other competitors in the future.

The global Dengue Vaccine Market is estimated to account for US$ 1,262.0 Mn in terms of value by the end of 2027. More clinical trials and research studies dedicated to identifying novel vaccine formulations are being fueled by a variety of worldwide collaborations including healthcare stakeholders from diverse institutional settings. Because of the highest dengue fever concentration and the existence of reputable regional pharmaceutical giants, the majority of growth is expected to stay centred in the Asia-Pacific area.

Up until now, the industry has only seen one big breakthrough in terms of vaccination availability, a tendency that is projected to fade away when businesses disclose their findings by the end of 2021. Multiple vaccine candidates are predicted in the future decade as a result of this. During the COVID-19 pandemic, major manufacturers have diverted existing production units to the development of an anti-SARS CoV-2 vaccine, as evidenced by Takeda Pharmaceutical's ad hoc surrender of its facility at IDT Biologika GmbH to Johnson and Johnson to manufacture single-shot COVID-19 vaccines.

Dengue fever has been far more common in recent decades, according to the World Health Organization. Because the vast majority of cases are asymptomatic, moderate, or self-managed, the true incidence of infections is greatly underestimated. According to one estimate, 390 million dengue virus infections occur each year (95 percent credible interval 284-528 million), with 96 million showing clinical symptoms.

Dengue epidemics do occur in the continental United States, according to the Centers for Disease Control and Prevention (CDC). These epidemics, however, are widespread in the US's overseas territories, such as Puerto Rico, the US Virgin Islands, and American Samoa. On the mainland, outbreaks were common in Hawaii (2015), Florida (2013), and Texas (2013, 2020). (2013).

Over the forecast period, the worldwide Dengue Vaccine Market is predicted to rise due to rising dengue prevalence. According to the Pan American Health Organization, a total of 1,191,815 cases of dengue fever were recorded in the Americas area between epidemiological weeks 1 and 22 of 2019, with 546,589 cases being laboratory-confirmed and 5,599 being categorised as severe dengue.

Mosquito-borne illness is becoming a greater hazard to local communities across Mexico, according to the World Mosquito Program. In recent years, there have been a number of large-scale dengue outbreaks, with infection rates expected to rise by 40% in the next five decades. As a result, in recent years, government measures to support a widespread vaccination campaign have risen.